Bright Minds Biosciences Inc (DRUG)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $227.96M
Last updated: Nov 17, 2026 at 4:10 PM ET
Bright Minds Biosciences Inc (DRUG) Statistics
Bright Minds Biosciences (DRUG) has a market cap of $227.96M. Its share count is up 38.77% from a year earlier.
Total Valuation
| Market Cap | $227.96M |
|---|---|
| Latest price (Nov 17, 2026) | $20.51 |
Key Dates
The next earnings report is expected on Dec 22, 2026, covering the quarter ending Sep 30, 2026.
| Next Earnings Date | Dec 22, 2026 (expected) |
|---|---|
| Last Earnings Date | Aug 14, 2026 |
| Fiscal Year End | September |
Price Statistics
The stock is down 64.57% over 52 weeks and trades 56.49% below its 50-day average.
| Beta (1Y) | 1.41 |
|---|---|
| 52-Week Change | -64.57% |
| 1-Month Change | -61.89% |
| 3-Month Change | -75.80% |
| 6-Month Change | -72.48% |
| 5-Year Change | +54.44% |
| Total Return (1Y) | -64.57% |
| Total Return (3Y CAGR) | +152.97% |
| Total Return (5Y CAGR) | -4.08% |
| Return vs SPY (1Y) | -76.03% |
| Max Drawdown (1Y) | -80.25% |
| Max Drawdown (3Y) | -80.25% |
| Sharpe Ratio (1Y) | -1.03 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $47.14 |
| 200-Day Average | $69.54 |
| 52-Week Range | $17.40 to $123.75 |
| RSI (14 Days) | 26.5 |
| Average Volume (20 Days) | 291.39K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 121.97x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 121.97x |
|---|---|
| Quick Ratio | 121.97x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on invested capital is -11.21% over the last 12 months, against a 5-year average of -69.39%.
| Return on Equity (ROE) | -8.21% |
|---|---|
| Return on Assets (ROA) | -8.14% |
| Return on Invested Capital (ROIC) | -11.21% |
| ROE (5Y Average) | -72.62% |
| ROA (5Y Average) | -66.77% |
| ROIC (5Y Average) | -69.39% |
Scores
DRUG has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was CAD 0 over the last 12 months.
| Revenue | CAD 0 |
|---|---|
| Gross Profit | CAD -72.09K |
| Operating Income | CAD -39.87M |
| Pretax Income | CAD -24.75M |
| Net Income | CAD -24.75M |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 99.18% of the CAD 310.84M in total assets.
| Working Capital | CAD 308.24M |
|---|---|
| Shareholder Equity | CAD 308.30M |
| Total Assets | CAD 310.84M |
| Total Liabilities | CAD 2.55M |
Balance sheet as of Jun 30, 2026.
Stock Splits
The last split was a 1-for-5 reverse split on Jul 14, 2023.
| Last Split Date | Jul 14, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:5 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About DRUG
What is DRUG's market cap?
Bright Minds Biosciences has a market cap of $227.96M.
How many shares of DRUG are outstanding?
Bright Minds Biosciences has 9.83M shares outstanding. The count is up 38.77% from a year earlier.
Does DRUG pay a dividend?
No. Bright Minds Biosciences does not pay a dividend.
DRUG pages: Overview, Charting, Financials, Statistics, Competitors